MYGN - ミリアド・ジェネティックス (Myriad Genetics Inc.)

MYGNのニュース

   Global Genetic Testing Market Outlook to 2022 Featuring Abbott Laboratories, Roche Diagnostics, Myriad Genetics, Thermo Fisher Scientific, Hologic, Cepheid, Agilent Technologies, and QIAGEN  2020/12/16 14:00:00 PR Newswire
DUBLIN, Dec. 16, 2020 /PRNewswire/ -- The "Global Genetic Testing Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering. "Global Genetic Testing Market Outlook 2022" provides a detailed analysis of the genetic testing market. The report also provides insight…
   Dec 15, 2020 – Glenview Capital Administration Buys Myriad Genetics Inc, Medtronic PLC, Amgen Inc, Sells Nuance Communicat  2020/12/16 05:37:30 Fintech Zoom
Dec 15, 2020 - Glenview Capital Administration Buys Myriad Genetics Inc, Medtronic PLC, Amgen Inc, Sells Nuance Communications Inc, ViacomCBS Inc, HCA Healthcare Inc -
   Genetic Testing Market 2020 Global Exclusive Analysis by Leading Players Overview | Abbott Laboratories, Bio-Rad Laboratories, Inc., Illumina Inc., Myriad Genetics, Inc., PerkinElmer Inc., QIAGEN N. V., Quest Diagnostics Incorporated  2020/12/15 13:26:58 OpenPR
Market Synopsis of Global Genetic testing Market: Genetic Testing Market is expected to grow at CAGR of 11.50% to reach USD 22834.19 million till 2024, revealed by Market Research Future (MRFR) with Global Genetic Testing Market Analysis by by Type, Method,
   Global Clinical Oncology Next Generation Sequencing Market Vigorous Growth 2020-2027 | Top Companies-F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., Thermo Fisher Scientific, Myriad Genetics Inc., BGI, Perkin Elmer, Inc  2020/12/10 15:45:51 OpenPR
“Global Clinical Oncology Next Generation Sequencing Market- Industry Trends and Forecast to 2027” Worldwide Industry Size, Offer and trends analysis during Period. Clinical Oncology Next Generation Sequencing Market report is a thoughtful analysis of the market presenting the propelled situation
   Preventive Healthcare Technologies And Services Market With Covid 19 Impact Analysis | Key Players: Omnicell Inc., Merck & Co. Inc., McKesson Corporation, GlaxoSmithKline plc., Medtronic, Quest Diagnostics Inc., Alere, Myriad Genetics Inc.  2020/12/09 07:13:12 OpenPR
The Preventive Healthcare Technologies And Services Market (2020) research report explores the market in terms of Revenue And Emerging Market Trends and Drivers and includes an up to date analysis and forecasts for various market segments, major players, and all
   Myriad Genetics Earnings and Growth Analysis : Stock market Insights & financial analysis  2020/11/09 14:39:00 Stock Market Daily
Myriad Genetics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Myriad Genetics Q1 2021 Earnings Preview (NASDAQ:MYGN)  2020/11/08 22:35:42 Seeking Alpha
Myriad Genetics (NASDAQ:MYGN) is scheduled to announce Q1 earnings results on Monday, November 9th, after market close. The consensus EPS Estimate is -$0.3
   Liquid Biopsy Market (COVID-19 Impact Analysis) 2020 Outlook Industry Analysis, Size, Share, Growth, Trends And Forecast, Leading Players are Eurofins Scientific, QIAGEN, Myriad Genetics, Genomic Health, RainDance Technologies  2020/10/27 12:23:49 OpenPR
This Liquid Biopsy Market research report makes available state-of-the-art information about the entire market along with the holistic view of the market. This global market research report displays a complete overview of the market, including myriad of aspects such as
   Myriad Genetics (NASDAQ:MYGN) Stock Price Up 5.1%  2020/10/23 10:30:43 Zolmax News
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) rose 5.1% on Wednesday . The company traded as high as $14.07 and last traded at $14.02. Approximately 635,557 shares changed hands during trading, a decline of 37% from the average daily volume of 1,013,374 shares. The stock had previously closed at $13.34. MYGN has been the topic of […]
   Financial Analysis: Myriad Genetics (NASDAQ:MYGN) & Navidea Biopharmaceuticals (NASDAQ:NAVB)  2020/10/22 09:04:47 Dakota Financial News
Myriad Genetics (NASDAQ:MYGN) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Profitability This table compares Myriad Genetics and Navidea Biopharmaceuticals’ net margins, return on equity and […]
   Myriad Genetics Earnings and Growth Analysis : Stock market Insights & financial analysis  2020/11/09 14:39:00 Stock Market Daily
Myriad Genetics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Myriad Genetics Q1 2021 Earnings Preview (NASDAQ:MYGN)  2020/11/08 22:35:42 Seeking Alpha
Myriad Genetics (NASDAQ:MYGN) is scheduled to announce Q1 earnings results on Monday, November 9th, after market close. The consensus EPS Estimate is -$0.3
   Liquid Biopsy Market (COVID-19 Impact Analysis) 2020 Outlook Industry Analysis, Size, Share, Growth, Trends And Forecast, Leading Players are Eurofins Scientific, QIAGEN, Myriad Genetics, Genomic Health, RainDance Technologies  2020/10/27 12:23:49 OpenPR
This Liquid Biopsy Market research report makes available state-of-the-art information about the entire market along with the holistic view of the market. This global market research report displays a complete overview of the market, including myriad of aspects such as
   Myriad Genetics (NASDAQ:MYGN) Stock Price Up 5.1%  2020/10/23 10:30:43 Zolmax News
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) rose 5.1% on Wednesday . The company traded as high as $14.07 and last traded at $14.02. Approximately 635,557 shares changed hands during trading, a decline of 37% from the average daily volume of 1,013,374 shares. The stock had previously closed at $13.34. MYGN has been the topic of […]
   Financial Analysis: Myriad Genetics (NASDAQ:MYGN) & Navidea Biopharmaceuticals (NASDAQ:NAVB)  2020/10/22 09:04:47 Dakota Financial News
Myriad Genetics (NASDAQ:MYGN) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Profitability This table compares Myriad Genetics and Navidea Biopharmaceuticals’ net margins, return on equity and […]

calendar